Guardant Health Inc
NASDAQ:GH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.07
36.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Guardant Health Inc
Guardant Health Inc
Revenue
Guardant Health Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Guardant Health Inc
NASDAQ:GH
|
Revenue
$692.3m
|
CAGR 3-Years
26%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
DaVita Inc
NYSE:DVA
|
Revenue
$12.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Revenue
$9.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
CVS Health Corp
NYSE:CVS
|
Revenue
$368.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Cigna Corp
NYSE:CI
|
Revenue
$232.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
21%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Revenue
$12.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
Guardant Health Inc
Revenue Breakdown
Breakdown by Geography
Guardant Health Inc
|
Total Revenue:
563.9m
USD
|
|
United States:
526.5m
USD
|
|
International:
37.4m
USD
|
Breakdown by Segments
Guardant Health Inc
Guardant Health Inc
Glance View
Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.
See Also
What is Guardant Health Inc's Revenue?
Revenue
692.3m
USD
Based on the financial report for Sep 30, 2024, Guardant Health Inc's Revenue amounts to 692.3m USD.
What is Guardant Health Inc's Revenue growth rate?
Revenue CAGR 5Y
30%
Over the last year, the Revenue growth was 29%. The average annual Revenue growth rates for Guardant Health Inc have been 26% over the past three years , 30% over the past five years .
You don't have any saved screeners yet
